

Special Issue

Development of Novel Nanomedicines for Combination Therapy and Theranostic Applications

Message from the Guest Editor

This Special Issue aims to highlight recent advances in the development of novel nanotherapeutics for combination therapy and theranostic applications in cancer treatment. Original research articles and reviews are welcome for this Special Issue. Research areas may include (but are not limited to) the following:

- Synthesis and characterisation of novel nanomaterials for combination therapies and/or theragnostic applications,
- Multifunctionalisation strategies to develop novel theragnostic drug delivery systems,
- Nanoformulations coloaded different therapeutic agents,
- Cell-based delivery systems for theranostic applications,
- Novel nanosystems combining traditional chemotherapy with photothermal, photodynamic, radiotherapy, and immunotherapy,
- Safety evaluation of novel nanotherapeutics for combination therapies.

I look forward to receiving your contributions.

Guest Editor

Dr. Amalia Ruiz

Institute of Cancer Therapeutics, University of Bradford, Richmond Rd,
Bradford BD7 1DP, UK

Deadline for manuscript submissions

closed (20 August 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/116240

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).